严重急性呼吸综合征冠状病毒进入过程作为抗病毒治疗的靶点。

Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.

作者信息

Kuhn Jens H, Li Wenhui, Radoshitzky Sheli R, Choe Hyeryun, Farzan Michael

机构信息

Department of Microbiology and Molecular Genetics, Harvard Medical School, New England Primate Research Center, Southborough, MA, USA.

出版信息

Antivir Ther. 2007;12(4 Pt B):639-50.

PMID:17944271

Abstract

The identification in 2003 of a coronavirus as the aetiological agent of severe acute respiratory syndrome (SARS) intensified efforts to understand the biology of coronaviruses in general and SARS coronavirus (SARS-CoV) in particular. Rapid progress was made in describing the SARS-CoV genome, evolution and lifecycle. Identification of angiotensin-converting enzyme 2 (ACE2) as an obligate cellular receptor for SARS-CoV contributed to understanding of the SARS-CoV entry process, and helped to characterize two targets of antiviral therapeutics: the SARS-CoV spike protein and ACE2. Here we describe the role of these proteins in SARS-CoV replication and potential therapeutic strategies aimed at preventing entry of SARS-CoV into target cells.

摘要

2003年，一种冠状病毒被确认为严重急性呼吸综合征（SARS）的病原体，这加大了人们全面了解冠状病毒生物学特性，尤其是严重急性呼吸综合征冠状病毒（SARS-CoV）生物学特性的力度。在描述SARS-CoV基因组、进化和生命周期方面取得了迅速进展。血管紧张素转换酶2（ACE2）被鉴定为SARS-CoV的必需细胞受体，这有助于理解SARS-CoV的进入过程，并有助于确定两种抗病毒治疗靶点：SARS-CoV刺突蛋白和ACE2。在此，我们描述了这些蛋白质在SARS-CoV复制中的作用以及旨在防止SARS-CoV进入靶细胞的潜在治疗策略。